EU/3/19/2180

About

On 25 July 2019, orphan designation EU/3/19/2180 was granted by the European Commission to Aprea Therapeutics AB, Sweden, for 2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one (also known as APR-246) for the treatment of myelodysplastic syndromes.

Key facts

Active substance
2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one
Disease / condition
Treatment of myelodysplastic syndromes
Date of first decision
25/07/2019
Outcome
Positive
EU designation number
EU/3/19/2180

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Aprea Therapeutics AB
Nobels Vag 3
171 65 Solna
Sweden
Tel: +46 (0)8 524 861 82
E-mail: info@aprea.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating